CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Axim Biotechnologies, Inc.  (AXIM)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
 
 

AXIM's Revenue Year on Year Growth by Quarter and Year

Axim Biotechnologies,'s Revenue results by quarter and year



Select the Comparisons : Select the Ratio:                        
AXIM Revenue (in millions $) FY 2017 FY 2016 FY 2015 FY 2014
IV Quarter December - 0.01 0.04 -
III Quarter September - 0.01 0.01 0.01
II Quarter June - 0.01 - -0.05
I Quarter March 0.02 0.01 -0.06 0.00
FY   0.02 0.04 -0.01 -0.04

Financial Statements
Axim Biotechnologies,'s first quarter 2017 Revenue $ 0.02 millions AXIM's Income Statement
Axim Biotechnologies,'s first quarter 2016 Revenue $ 0.01 millions Quarterly AXIM's Income Statement
AXIM's Growth by Division See AXIM's Growth by Segment

AXIM Revenue ( Y/Y Growth %) 2017
2016 2015 2014
IV Quarter December - -75 % - -
III Quarter September - 0 % 0 % -
II Quarter June - - - -
I Quarter March 86.2 % - - -
FY   - - - -



AXIM Revenue Growth Comment
Axim Biotechnologies, Inc. achieved in the first quarter, above Company average Revenue rise of 86.2% year on year, to $ 0.02 millions.

Looking into first quarter results within Biotechnology & Drugs industry 28 other companies have achieved higher Revenue growth. While Axim Biotechnologies, Inc.' s Revenue jump of 86.2% ranks overall at the positon no. 696 in the first quarter.



Revenue Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #29
Healthcare Sector #110
Overall #696
Revenue Y/Y Growth Statistics
High Average Low
61.49 % 5.06 % -67.02 %
(Jun 30 2015)   (Dec 31 2016)

You need to upgrade your Flash Player

Other Revenue Growth
Biotechnology & Drugs Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AXIM's Revenue Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for AXIM's Competitors
Revenue Growth for Axim Biotechnologies,'s Suppliers
Revenue Growth for AXIM's Customers

You may also want to know
AXIM's Annual Growth Rates AXIM's Profitability Ratios AXIM's Asset Turnover Ratio AXIM's Dividend Growth
AXIM's Roe AXIM's Valuation Ratios AXIM's Financial Strength Ratios AXIM's Dividend Payout Ratio
AXIM's Roa AXIM's Inventory Turnover Ratio AXIM's Growth Rates AXIM's Dividend Comparisons



Companies with similar Revenue jump for the quarter ending Mar 31 2017 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2017
Catasys, Inc.  150.27 %$ 150.275 millions
Catalyst Biosciences, Inc.  148.62 %$ 148.624 millions
Viveve Medical, Inc.  136.84 %$ 136.838 millions
Flex Pharma, Inc.  134.72 %$ 134.724 millions
China Longyi Group International Holdings Ltd  126.39 %$ 126.388 millions
Neos Therapeutics, Inc.  117.85 %$ 117.847 millions
Hemispherx Biopharma Inc  115.38 %$ 115.385 millions
Novabay Pharmaceuticals, Inc.  115.30 %$ 115.300 millions
Aveo Pharmaceuticals Inc  110.47 %$ 110.474 millions
Egalet Corp  103.79 %$ 103.793 millions
China Yct International Group, Inc.  102.56 %$ 102.562 millions
Delcath Systems, Inc.  100.81 %$ 100.811 millions
Green Meadow Products, Inc.  100.00 %$ 100.000 millions
Uluru Inc.  99.57 %$ 99.571 millions
Juno Therapeutics, Inc.  97.72 %$ 97.719 millions
Biocryst Pharmaceuticals Inc  95.79 %$ 95.788 millions
Kite Pharma, Inc.  91.85 %$ 91.847 millions
Neurometrix, Inc.  89.26 %$ 89.260 millions
Eleven Biotherapeutics, Inc.  85.59 %$ 85.590 millions
Nantkwest, Inc.  83.33 %$ 83.333 millions
Psivida Corp.  82.10 %$ 82.099 millions
Cempra, Inc.  81.86 %$ 81.859 millions
Vertex Pharmaceuticals Inc  79.54 %$ 79.541 millions
Ani Pharmaceuticals Inc  78.20 %$ 78.195 millions
Caredx, Inc.  76.53 %$ 76.532 millions
Vivus Inc  76.27 %$ 76.273 millions
Anavex Life Sciences Corp.  73.19 %$ 73.195 millions
Keryx Biopharmaceuticals Inc  73.17 %$ 73.172 millions
Cytosorbents Corp  72.00 %$ 72.000 millions
Corcept Therapeutics Inc  71.84 %$ 71.839 millions